Verve Ventures的动态

Our lab alum, YongTae "Tony" Kim, is the Co-Founder and CEO of a biotechnological startup, Mepsgen (Co-founded by Bob Langer at MIT). Their cutting-edge solutions include NanoCalibur, a high-precision system for nanoparticle synthesis, and ProMEPS, an automated microphysiological modeling system. Mepsgen caters to fields such as drug delivery, efficacy testing, and microphysiological system (organ-on-a-chip) research. By combining scalability, precision, and user-friendly designs, the company empowers researchers and developers to streamline processes and achieve breakthroughs in pharmaceutical and therapeutic applications. ---------------------------------------- #biotechnology #biotech #nanoparticle #microfluidics #drugdelivery

It warms my heart to see scientific papers in healthcare that use futures methods! In this paper, authors generated scenarios that they call horizons to demonstrate how generative AI could contribute to driving productivity and scientific breakthroughs in pharmaceutical R&D. ?????????????? ??: GenAI tools are already speeding up R&D milestones, boosting quality, and increasing productivity in pharma today. ?????????????? ??: Rapid progress will unlock smarter virtual assistance, digital therapeutics, and deeper GenAI applications over the next 2–5 years. ?????????????? ??: Emerging bioconvergence will fuse AI with biotechnology, engineering, and medicine, revolutionizing pharmaceutical R&D through interdisciplinary breakthroughs.

I've had no time or space (pun intended) to share this, but ... ... recently I had the most fun putting pen to digital paper with Samuel Winnall from Next Sequence? and co-writing the last article in his #SpaceBio article series Biomanufacturing is tough. Drug formulations are more complex than ever, capacity to produce biologics is lagging behind demand, lab to production scale remains poorly predictable. Should we perhaps venture out to space to resolve these challenges? Find out our thoughts here: https://lnkd.in/eMGb9Te4

?? Archon Biosciences Emerges with $20M Seed Funding to Transform Biologic Drug Development TL;DR: ? Startup launches with groundbreaking "antibody cage" technology ? Founded by UW Institute for Protein Design alumni ? Backed by Nobel laureate David Baker ? 17-person team funded through 2026 Exciting developments in the protein design space! Archon Biosciences has emerged from stealth mode, introducing a revolutionary approach to enhancing biologic drugs through computational protein design. Led by CEO James Lazarovits, Archon's innovative "antibody cage" technology allows precise modification of antibody properties without altering their amino acid sequences - potentially streamlining drug development while maintaining therapeutic efficacy. The $20M seed round was led by Madrona Ventures, with Alexandria Venture Investments among key participants. The company joins an impressive lineup of ventures connected to David Baker's lab, including Sana Biotechnology and Lyell Immunopharma. What sets Archon apart? Their computational approach to molding antibodies into specific nanostructures could be a game-changer for drug distribution and binding properties. Looking ahead: The team is focused on identifying their lead program and pursuing additional funding for clinical trials. ?? What are your thoughts on computational approaches to drug development? How do you see this technology impacting the future of biologics? #Biotech #DrugDevelopment #ProteinDesign #Innovation #BiotechNews #intelligencesimplified #pharma #biotech #biodatastudio

??Will we manufacture all pharmaceutical products in space? Unlikely. Will it become economically viable to leverage space infrastructure to crack the hardest manufacturing challenges? We believe so. ?? In this final instalment of our #spaceBio series, we’ve partnered with Nelli Morgulchik at Hummingbird Ventures to discuss the science and key players who are taking on the challenge of space based pharmaceutical manufacturing! ??From the incumbent juggernaut Redwire Space, to the revolutionary Varda Space Industries, and the new kids on the block such as BioOrbit, Prometheus Life Technologies and Frontier Space Technologies, space based pharma is the one to watch! https://lnkd.in/eNd9aPw3

Japan-based startup ThinkCyte, a biotechnology company pioneering novel artificial intelligence (AI)-based cell analysis and sorting instruments, will begin the pre-commercial launch of its new cell analysis platform, VisionCyte. https://lnkd.in/dWgWzz3m ThinkCyte #ArtificialIntelligence #LaboratoryAutomation #lifescienceresearch

?? Cell Sorting Market: Revolutionizing Cell Analysis ?? The Cell Sorting Market was valued at US$ 664.09 Mn in 2023 and is projected to grow at a robust CAGR of 10.5%, reaching nearly US$ 1335.86 Mn by 2030. Market Overview: Cell sorting is a critical process in biotechnology and research, involving the collection and separation of cells based on their type. It is widely used in applications such as biomedical research, drug discovery, and clinical diagnostics. Key methods include: 1?? Single-cell sorting 2?? Fluorescent-activated cell sorting (FACS) - the most commonly used technique 3?? Magnetic-activated cell sorting (MACS) ?? As advancements in technology continue, the demand for precise and efficient cell sorting methods is driving the market forward. ?? Join the movement to explore innovations shaping the future of cell sorting! #CellSorting #Biotechnology #LifeSciences #CellAnalysis #FACS #BiomedicalResearch #DrugDiscovery #ClinicalDiagnostics #HealthcareInnovation #MarketInsights Let’s discuss insights and opportunities:https://lnkd.in/gDDsu-Pt

I recently attended the "Advances in Drug Discovery and Development 2024" symposium, and it was truly an eye-opening experience! ?? ?? From exploring AI-driven drug discovery, biomolecular engineering to leveraging quantum modeling and machine learning in drug development, the sessions shed light on how cutting-edge technology is shaping the future of medicine. Here are some of the key takeaways: ?? Quantum modeling and machine learning are generating billions of novel compounds with enhanced binding, streamlining the drug discovery process. ?? Use of A.I generative models is expediting antibiotic discovery by creating novel compounds from existing repurposing drug banks with to combat AMR. ?? Small molecule ligands for RNA-targeted therapies are emerging as a frontier in precision medicine, opening doors to treatments for previously untreatable conditions. These sessions have enabled me to truly appreciate how the nature of drug discovery and development industry is truly interdisciplinary and is always evolving as new technologies and innovations arise! ?? A huge thank you to Technology Networks for organizing such a thought-provoking event with an incredible line-up of speakers. I'm excited to see how these innovations will drive the next wave of pharmaceutical and biopharmaceutical breakthroughs! ?? #drugdiscovery #precisionmedicine #innovation #drugdevelopment #pharmacy #onlinesymposium

?? Exciting News! ?? We're thrilled to announce the release of our latest Application Note: "Characterizing Small Molecule Hits from DNA-Encoded Library Screenings by Focal Molography" In this groundbreaking study, we delve into the cutting-edge intersection of two powerful technologies: DNA-encoded library (DEL) screenings and focal Molography. DNA-encoded libraries (DELs) offer an unparalleled diversity of small molecule compounds, each tagged with a unique DNA barcode. Meanwhile, focal Molography enables real-time, label-free monitoring of molecular binding events, providing valuable insights into biomolecular interactions. Our Application Note showcases how this innovative synergy enhances the drug discovery process. By leveraging focal Molography to characterize small molecule hits from DEL screenings, researchers gain deeper insights into binding kinetics, affinity, and specificity, paving the way for the development of novel therapeutics. Stay ahead of the curve in drug discovery research with our latest insights! #DrugDiscovery #DEL #FocalMolography #Biotech #Pharma #Innovation #Research #Science #Bioanalytics #LabelFreeDetection #BiomolecularInteractions

Excited to have led the closing panel entitled "Bridging Science and Investment" in San Diego, CA. Joined by Dr. Sanjeev Thohan (Cogentis Therapeutics, Inc./Phoenix Molecular Designs) and Dr. Yuhua Ji (Grace Science, LLC ), we explored the intersection of scientific innovation and investment strategies. Key topics of this thought-provoking panel included: - Strategic investment approaches in the evolving biotech landscape - The critical role of venture capital in accelerating drug discovery - Innovative funding models for cutting-edge pharmaceutical research - The future of biotechnologies and the investment opportunities they present Thank you to the panelists for sharing their invaluable insights. Our discussion underscored the vital role of strategic investments in driving innovation and shaping the future of drug discovery and development. Together, we are paving the way for groundbreaking advancements in biotech. #biotechnology #MedicinalChemistry, #strategy #drugdevelopment Proventa International #Bio2024 BIO International Convention #DrugDiscovery #Investment #VentureCapital #Biotech #SanDiego American Association for Precision Medicine (AAPM) WISE World Investors & Entrepreneurs Society Agility Pharmaceuticals Precision BioPharma #ai #news